Sophiris Bio(加拿大)

Sophiris Bio

加拿大SophirisBiowww.sophirisbio.comProtoxTherapeuticsInc.(温哥华，Vancouver)宣布公司就PRX302药物项目己向美国FDA提出摄护腺癌治疗药物的研究中新药申请(investigationalnewdrug，IND)。一旦在FDA的IND案通过，公司预期便可以在下一年进行复发型部位固定摄护腺癌临床期测试。2012年加拿大ProtoxThe rapeuticsInc改名为SophirisBio ProtoxTherapeuticsusesgeneticengineeringtotransformnaturallyoccurringproteinsintonoveltargetedtherapeuticsforthetreatmentofprostatediseasesandvariouscancers.Protoxisadvancingapipelineofclinical-stageproductcandidatesderivedfromitsPORxin™andINxin™technologyplatforms.Protox’sleaddrugscurrentlyinclinicaldevelopmentincludePRX302forthetreatmentofbenignprostatichyperplasia(BPH,commonlyknownasenlargedprostate)andlocalizedprostatecancer,aswellasPRX321forprimarybraincancer(glioblastomamultiformeandastrocytoma).